Oncuria
Commercial- Indications
- Bladder cancer
Company intelligence / Profile preview
Nonagen Bioscience develops advanced diagnostic tests focused on oncology. Its lead product, Oncuria®, a multiplex immunoassay using urine samples to detect and monitor bladder cancer, has received FDA Breakthrough Device Designation. Pivotal clinical trials are nearing completion as of mid–2025. The company’s pipeline includes additional diagnostics targeting breast/prostate cancers and liver fibrosis. Commercialization partnerships are underway.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nonagen Bioscience.